Search - tctmd.com

Displaying 221 - 240 of 375

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2016

Shelley Wood

April 29, 2016

News Daily News

USPSTF 收紧一级预防的建议，称阿司匹林应只在高危人群中使用

Michael O'Riordan

April 12, 2016

News Conference News ACC 2016

Comparing the Novel Oral Anticoagulants: Effectiveness Similar, but Apixaban May Come With Less Bleeding

Todd Neale

April 06, 2016

News Daily News

Las Últimas Directrices Norteamericanas Reducen la Duración del Tratamiento Antiplaquetario Doble de 12 a 6 Meses en Pacientes Estables que Reciben un SLF

Yael L. Maxwell

March 30, 2016

News Industry News

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

March 01, 2016

News Daily News

Ticagrelor Loading Dose Provides Faster Platelet Inhibition Than Clopidogrel in Ad Hoc PCI

L.A. McKeown

February 09, 2016

News Daily News

In the Real World, Dabigatran and Warfarin Give Equal Stroke Protection to A-fib Patients

Todd Neale

January 25, 2016

News Daily News

FDA 的前职员表示，各抗血栓试验的缺失数据使得药物作用蒙上疑云

Shelley Wood

January 18, 2016

News Opinion Editor's Corner

Las 10 Noticias de TCTMD Más Leídas de 2015

Shelley Wood

December 29, 2015

News Daily News

三联疗法特别是普拉格雷会增加急性心梗患者的出血风险

Yael L. Maxwell

December 22, 2015

News Daily News

Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI

Yael L. Maxwell

December 22, 2015

News Daily News

El Tratamiento Triple, sobre todo con Prasugrel, Aumenta el Riesgo Hemorrágico de los IAM

Yael L. Maxwell

December 22, 2015

News Daily News

Early Data Show Promise for Reversible, Fast-Acting, Antiplatelet Drug PZ-128

Caitlin E. Cox

December 20, 2015

News Industry News

First Patients Enrolled in the Gore RELINE MAX Clinical Study

December 15, 2015

News Daily News

Study Affirms Cost-Effectiveness of Watchman LAA Closure Device for Stroke Reduction

L.A. McKeown

December 14, 2015

News Daily News

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

Yael L. Maxwell

December 14, 2015

Presentation

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Presenter: Vivek Y. Reddy

December 13, 2015

News Industry News

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

November 23, 2015

News Conference News AHA 2015

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Todd Neale

November 12, 2015

News Conference News AHA 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Yael L. Maxwell

November 10, 2015

Advertisement

TCTMD’s Top 10 Most Popular Stories for April 2016

USPSTF 收紧一级预防的建议，称阿司匹林应只在高危人群中使用

Comparing the Novel Oral Anticoagulants: Effectiveness Similar, but Apixaban May Come With Less Bleeding

Las Últimas Directrices Norteamericanas Reducen la Duración del Tratamiento Antiplaquetario Doble de 12 a 6 Meses en Pacientes Estables que Reciben un SLF

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

Ticagrelor Loading Dose Provides Faster Platelet Inhibition Than Clopidogrel in Ad Hoc PCI

In the Real World, Dabigatran and Warfarin Give Equal Stroke Protection to A-fib Patients

FDA 的前职员表示，各抗血栓试验的缺失数据使得药物作用蒙上疑云

Las 10 Noticias de TCTMD Más Leídas de 2015

三联疗法特别是普拉格雷会增加急性心梗患者的出血风险

Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI

El Tratamiento Triple, sobre todo con Prasugrel, Aumenta el Riesgo Hemorrágico de los IAM

Early Data Show Promise for Reversible, Fast-Acting, Antiplatelet Drug PZ-128

First Patients Enrolled in the Gore RELINE MAX Clinical Study

Study Affirms Cost-Effectiveness of Watchman LAA Closure Device for Stroke Reduction

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content